Corcept Therapeutics
CORT
287 hedge funds and large institutions have $2.36B invested in Corcept Therapeutics in 2024 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 109 increasing their positions, 90 reducing their positions, and 40 closing their positions.
40% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 40
21% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 90
7.13% more ownership
Funds ownership: 83.49% → 90.62% (+7.1%)
5% more funds holding
Funds holding: 273 → 287 (+14)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
15% less capital invested
Capital invested by funds: $2.79B → $2.36B (-$432M)
21% less call options, than puts
Call options by funds: $65.5M | Put options by funds: $83M
Top Buyers
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$40M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$17.3M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$16.2M |
| 4 |
Man Group
London,
United Kingdom
|
+$15.9M |
| 5 |
Cerity Partners
New York
|
+$14.2M |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$38.7M |
| 2 |
Morgan Stanley
New York
|
-$25.5M |
| 3 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$15.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$12.4M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$10.9M |
CORT Hedge Fund Activity: Q1 2024 in Review
287 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2024, worth a combined $2.36B — down 15% from $2.79B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new CORT positions and 40 closed out — a net gain of 16 holders — while 109 added to existing stakes and 90 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $40M. The largest seller was Federated Hermes, cutting an estimated $38.7M.
- 287 institutional investors held Corcept Therapeutics (CORT) as of Q1 2024, up from 273 in Q4 2023.
- Funds reported $2.36B of Corcept Therapeutics stock for Q1 2024, down 15% quarter-over-quarter.
- 56 funds opened new Corcept Therapeutics positions in Q1 2024 and 40 closed out, a net change of +16 holders.
- The largest Corcept Therapeutics buyer in Q1 2024 was First Trust Advisors, an estimated $40M added.
- The largest Corcept Therapeutics seller in Q1 2024 was Federated Hermes, an estimated $38.7M sold.
Based on aggregated 13F filings for Q1 2024.